Can Shire make the most of Baxalta's hemophilia meds?

Shire ($SHPG) CEO Flemming Ornskov says his own goals for cost savings, postmerger with Baxalta ($BXLT), are higher than the company's stated $500 million. But analysts are still skeptical of the deal; they're particularly worried about stepped-up competition in hemophilia with new meds hitting the market. More from FiercePharma

Suggested Articles

Enhertu previously topped chemo at helping heavily pretreated patients with HER2-positive breast cancer live longer.

Disease awareness campaigns need to go where the patients are, and today that means digital. That's been even more important during the pandemic.

Changing adult healthcare habits is difficult, but GSK's general vaccine awareness campaign begun this summer reports early successes.